T2 Biosystems, Inc. (NASDAQ:TTOO) Short Interest Update

T2 Biosystems, Inc. (NASDAQ:TTOO) saw a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 942,500 shares, an increase of 50.8% from the December 15th total of 624,900 shares. Currently, 10.1% of the company’s shares are short sold. Based on an average trading volume of 900,900 shares, the days-to-cover ratio is presently 1.0 days.

T2 Biosystems Stock Down 3.4 %

Shares of NASDAQ TTOO traded down $0.01 during trading on Wednesday, hitting $0.28. 773,186 shares of the company traded hands, compared to its average volume of 856,840. The company has a 50-day moving average price of $0.45 and a 200-day moving average price of $2.18. T2 Biosystems has a 1 year low of $0.28 and a 1 year high of $6.95.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on shares of T2 Biosystems in a research report on Monday. They issued a “sell” rating on the stock.

Institutional Investors Weigh In On T2 Biosystems

An institutional investor recently bought a new position in T2 Biosystems stock. Armistice Capital LLC acquired a new stake in T2 Biosystems, Inc. (NASDAQ:TTOO) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 1,658,000 shares of the medical equipment provider’s stock, valued at approximately $8,854,000. Armistice Capital LLC owned approximately 9.49% of T2 Biosystems at the end of the most recent reporting period. 23.18% of the stock is owned by hedge funds and other institutional investors.

About T2 Biosystems

T2 Biosystems, Inc, an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.